Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Interest Expenses (2022 - 2026)

TriSalus Life Sciences has reported Interest Expenses over the past 5 years, most recently at $1.4 million for Q1 2026.

  • For Q1 2026, Interest Expenses rose 18.78% year-over-year to $1.4 million; the TTM value through Mar 2026 reached $5.8 million, up 34.33%, while the annual FY2025 figure was $5.5 million, 79.42% up from the prior year.
  • Interest Expenses for Q1 2026 was $1.4 million at TriSalus Life Sciences, down from $1.5 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $1.5 million in Q3 2025 and troughed at $1000.0 in Q4 2022.
  • A 5-year average of $720500.0 and a median of $972500.0 in 2024 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: crashed 40.0% in 2024 and later surged 40200.0% in 2025.
  • Year by year, Interest Expenses stood at $1000.0 in 2022, then surged by 200.0% to $3000.0 in 2023, then surged by 35500.0% to $1.1 million in 2024, then soared by 35.96% to $1.5 million in 2025, then decreased by 1.1% to $1.4 million in 2026.
  • Business Quant data shows Interest Expenses for TLSI at $1.4 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.